Epigenomics, BioChain Collaborate to Bring Colorectal Cancer Screening Technology to China | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics and clinical diagnostics firm BioChain today announced a collaboration to bring Epigenomics' Septin9-based colorectal cancer screening technology to China.

BioChain has obtained an exclusive license to develop and commercialize Septin9 in vitro diagnostic tests for colorectal cancer screening in the Chinese market, and in return, Epigenomics will receive upfront and minimum annual payments. It also will receive mid-single royalty payments if and when the product is approved by regulators in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.